Quarterly report pursuant to Section 13 or 15(d)

Deferred Research And Development Arrangement (Details)

v3.8.0.1
Deferred Research And Development Arrangement (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2003
Dec. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Deferred Research and Development Arrangement $ 393,750   $ 393,750     $ 450,000
Rexgene Biotech Co., Ltd. [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research and development arrangement, one-time fee         $ 1,500,000  
Reduction of research and development expenses 18,750 $ 18,750 $ 56,250 $ 56,250    
Research and development period     20 years      
Deferred Research and Development Arrangement $ 393,750   $ 393,750     $ 450,000
Royalties paid, percentage of net sales     3.00%